Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.596,07
0,29%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) Notizie

Nektar Therapeutics

NKTR
1,33
0,01 (0,76%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/3/202419:00PRNUSNektar Management to Present at the H.C. Wainwright 2nd..
05/3/202423:11EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202415:00PRNUSNektar Therapeutics Announces Initiation of Phase 2b..
04/3/202422:20EDGAR2Form 8-K - Current report
04/3/202422:15PRNUSNektar Therapeutics Reports Fourth Quarter and Year-End 2023..
04/3/202414:40EDGAR2Form 8-K - Current report
04/3/202414:30PRNUSNektar Therapeutics Announces $30 Million Private Placement..
28/2/202400:00PRNUSNektar Management to Present at the TD Cowen 44th Annual..
27/2/202400:00PRNUSNektar to Announce Financial Results for the Fourth Quarter..
23/2/202402:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202421:55EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:51EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:50EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:16EDGAR2Form 8-K - Current report
14/2/202423:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202422:25EDGAR2Form 8-K - Current report
04/1/202400:00PRNUSNektar Management To Present at the 42nd Annual J.P. Morgan..
16/12/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202318:18EDGAR2Form 144 - Report of proposed sale of securities
12/12/202300:00PRNUSNektar and Collaborators Present Preclinical Data on..
27/11/202322:55EDGAR2Form 8-K - Current report
21/11/202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202302:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202322:36EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:15EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:10EDGAR2Form 144 - Report of proposed sale of securities
07/11/202322:21EDGAR2Form 8-K - Current report
07/11/202322:15PRNUSNektar Therapeutics Reports Third Quarter 2023 Financial..
31/10/202323:00PRNUSNektar to Announce Financial Results for the Third Quarter..
13/10/202314:30PRNUSNektar Presents New Responder Data for Rezpegaldesleukin, a..
02/10/202315:00PRNUSNektar Therapeutics Announces Two Abstracts Accepted at EADV..
27/9/202315:00PRNUSNektar Therapeutics Announces New Clinical Study..
22/9/202302:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202323:06EDGAR2Form 144 - Report of proposed sale of securities
13/9/202315:00PRNUSNektar Therapeutics Announces Promising New Data from Phase..
08/9/202323:16EDGAR2Form 8-K - Current report
07/9/202300:00PRNUSNektar Therapeutics to Host Virtual Investor & Analyst Event..
18/8/202302:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202302:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 1,33 Min: 1,31 Max: 1,38
Chiusura: 1,32

La tua Cronologia

NASDAQ
NKTR
Nektar Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network